» Articles » PMID: 20333269

Advances in Nuclear Magnetic Resonance for Drug Discovery

Overview
Specialties Chemistry
Pharmacology
Date 2010 Mar 25
PMID 20333269
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND: Drug discovery is a complex and unpredictable endeavor with a high failure rate. Current trends in the pharmaceutical industry have exasperated these challenges and are contributing to the dramatic decline in productivity observed over the last decade. The industrialization of science by forcing the drug discovery process to adhere to assembly-line protocols is imposing unnecessary restrictions, such as short project time-lines. Recent advances in nuclear magnetic resonance are responding to these self-imposed limitations and are providing opportunities to increase the success rate of drug discovery. OBJECTIVE/METHOD: A review of recent advancements in NMR technology that have the potential of significantly impacting and benefiting the drug discovery process will be presented. These include fast NMR data collection protocols and high-throughput protein structure determination, rapid protein-ligand co-structure determination, lead discovery using fragment-based NMR affinity screens, NMR metabolomics to monitor in vivo efficacy and toxicity for lead compounds, and the identification of new therapeutic targets through the functional annotation of proteins by FAST-NMR. CONCLUSION: NMR is a critical component of the drug discovery process, where the versatility of the technique enables it to continually expand and evolve its role. NMR is expected to maintain this growth over the next decade with advancements in automation, speed of structure calculation, in-cell imaging techniques, and the expansion of NMR amenable targets.

Citing Articles

In-vivo and in-silico studies revealed the molecular mechanisms of phenolics as novel chemotherapy against benign prostatic hyperplasia via inhibition of 5α-reductase and α1-adrenoceptor.

Tusubira D, Munezero J, Agu P, Ajayi C, Oloro J, Namale N In Silico Pharmacol. 2023; 11(1):4.

PMID: 36873908 PMC: 9978050. DOI: 10.1007/s40203-023-00141-9.


Optimized Inhibitors of MDM2 via an Attempted Protein-Templated Reductive Amination.

van der Vlag R, Unver M, Felicetti T, Twarda-Clapa A, Kassim F, Ermis C ChemMedChem. 2019; 15(4):370-375.

PMID: 31774938 PMC: 7064911. DOI: 10.1002/cmdc.201900574.


A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53 osteosarcoma cells.

Skalniak L, Twarda-Clapa A, Neochoritis C, Surmiak E, Machula M, Wisniewska A FEBS J. 2019; 286(7):1360-1374.

PMID: 30715803 PMC: 6634946. DOI: 10.1111/febs.14774.


Human umbilical cord blood plasma as an alternative to animal sera for mesenchymal stromal cells in vitro expansion - A multicomponent metabolomic analysis.

Caseiro A, Ivanova G, Pedrosa S, Branquinho M, Georgieva P, Barbosa P PLoS One. 2018; 13(10):e0203936.

PMID: 30304014 PMC: 6179201. DOI: 10.1371/journal.pone.0203936.


NMRmix: A Tool for the Optimization of Compound Mixtures in 1D (1)H NMR Ligand Affinity Screens.

Stark J, Eghbalnia H, Lee W, Westler W, Markley J J Proteome Res. 2016; 15(4):1360-8.

PMID: 26965640 PMC: 4820789. DOI: 10.1021/acs.jproteome.6b00121.


References
1.
Roberts . Applications of NMR in drug discovery. Drug Discov Today. 2000; 5(6):230-240. DOI: 10.1016/s1359-6446(00)01479-3. View

2.
Ullman F, Boutellier R . Drug discovery: are productivity metrics inhibiting motivation and creativity?. Drug Discov Today. 2008; 13(21-22):997-1001. DOI: 10.1016/j.drudis.2008.06.015. View

3.
Livingstone C, Barton G . Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation. Comput Appl Biosci. 1993; 9(6):745-56. DOI: 10.1093/bioinformatics/9.6.745. View

4.
McGovern S, Helfand B, Feng B, Shoichet B . A specific mechanism of nonspecific inhibition. J Med Chem. 2003; 46(20):4265-72. DOI: 10.1021/jm030266r. View

5.
Lienemann K, Plotz T, Pestel S . NMR-based urine analysis in rats: prediction of proximal tubule kidney toxicity and phospholipidosis. J Pharmacol Toxicol Methods. 2008; 58(1):41-9. DOI: 10.1016/j.vascn.2008.06.002. View